# HealiRNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healirna

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.healrna.com
- Latest round: Angel (Sep 22, 2021)
- Investors on record: 3

## About

Established in 2021 and based in Suzhou, China, HealiRNA operates as a mRNA drug technology production platform that provides infectious disease vaccines, tumor vaccines, cell therapy and protein substitution based on mRNA technology. In March 2021, the company cooperates with Soochow University and Suzhou Nano Institute of Chinese Academy of Sciences. In April 2022, it was awarded as the national science and technology SMEs. In January 2025, it closed a venture funding from new investors Shenzhen Guozhong Venture Capital, Shenzhen Changying Enterprise Management, Vazyme Biotech Co.,Ltd., and returning investor GP Capital. In September, HealiRNA closed a strategic investment from new investors Leader Venture Capital and Xinchu Technology.

The company based on mRNA technology developing infectious disease vaccines, tumor vaccines, cell therapy and protein substitution. It provides nucleic acid drug development and production platform, including cell like system (CLS) development platform, superfluidic production platform and mRNA design and synthesis platform. Products include Pfizer, BioNTech and Moderna new crown mRNA vaccine.

The company generates revenue by providing mRNA drug R&D services, product pipelines cooperation, and selling its self-developed mRNA-based drugs for both human and animal applications in the future.

## Funding rounds

- Angel, Sep 22, 2021 — Hong Shan, GP Capital, Hyfinity Investments

## Investors

- Hong Shan — Angel
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Angel
- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Angel